Ironwood Pharmaceuticals, Inc. (IRWD)

Market Cap	1.30B
Revenue (ttm)	442.74M
Net Income (ttm)	-1.00B
Shares Out	156.53M
EPS (ttm)	-6.45
PE Ratio	n/a
Forward PE	10.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,109,094
Open	8.07
Previous Close	8.06
Day's Range	8.06 - 8.35
52-Week Range	7.53 - 15.70
Beta	0.55
Analysts	Strong Buy
Price Target	19.50 (+134.66%)
Earnings Date	May 2, 2024

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the tre...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2010
• Employees: 267
• Stock Exchange: NASDAQ
• Ticker Symbol: IRWD

Analyst Forecast

According to 4 analysts, the average rating for IRWD stock is "Strong Buy." The 12-month stock price forecast is $19.5, which is an increase of 134.66% from the latest price.

Price Target

$19.5

(134.66% upside)

Analyst Consensus: Strong Buy